- Home
- TRNR vs PPBT Comparison
TRNR vs PPBT Comparison
Compare TRNR & PPBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRNR
- PPBT
- Stock Information
- Founded
- TRNR 2017
- PPBT 2010
- Country
- TRNR United States
- PPBT Israel
- Employees
- TRNR N/A
- PPBT N/A
- Industry
- TRNR Consumer Electronics/Appliances
- PPBT Biotechnology: Pharmaceutical Preparations
- Sector
- TRNR Technology
- PPBT Health Care
- Exchange
- TRNR Nasdaq
- PPBT Nasdaq
- Market Cap
- TRNR 5.8M
- PPBT 6.2M
- IPO Year
- TRNR 2023
- PPBT N/A
- Fundamental
- Price
- TRNR $4.13
- PPBT $1.99
- Analyst Decision
- TRNR
- PPBT Strong Buy
- Analyst Count
- TRNR 0
- PPBT 1
- Target Price
- TRNR N/A
- PPBT $33.00
- AVG Volume (30 Days)
- TRNR 92.3K
- PPBT 22.1K
- Earning Date
- TRNR 08-14-2025
- PPBT 08-06-2025
- Dividend Yield
- TRNR N/A
- PPBT N/A
- EPS Growth
- TRNR N/A
- PPBT N/A
- EPS
- TRNR N/A
- PPBT N/A
- Revenue
- TRNR $6,972,000.00
- PPBT N/A
- Revenue This Year
- TRNR $578.14
- PPBT N/A
- Revenue Next Year
- TRNR $130.65
- PPBT N/A
- P/E Ratio
- TRNR N/A
- PPBT N/A
- Revenue Growth
- TRNR 373.32
- PPBT N/A
- 52 Week Low
- TRNR $3.61
- PPBT $1.94
- 52 Week High
- TRNR $536.30
- PPBT $13.95
- Technical
- Relative Strength Index (RSI)
- TRNR 42.51
- PPBT 33.60
- Support Level
- TRNR $3.82
- PPBT $2.17
- Resistance Level
- TRNR $4.09
- PPBT $2.36
- Average True Range (ATR)
- TRNR 0.32
- PPBT 0.16
- MACD
- TRNR 0.09
- PPBT -0.01
- Stochastic Oscillator
- TRNR 51.49
- PPBT 10.87
About TRNR Interactive Strength Inc.
Interactive Strength Inc provides an integrated home fitness platform that allows its customers to participate in interactive wellness and strength-based training sessions. Its health coaching services encompass guidance and coaching on nutrition, recovery, sleep, and other health and lifestyle categories. The company generates revenue from sales of its connected fitness products, membership revenue, and personal training revenue.
About PPBT Purple Biotech Ltd.
Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.